San Carlos, United States
Epinoma aims to revolutionize the biotechnology landscape by engineering proteins to manage biological systems, as highlighted in their slogan, "We engineer proteins that control the operating system of biology." Founded in 2020 and headquartered in the United States, the company is seated at the intersection of Biotechnology, Health Care, and Life Sciences.
Their pioneering platform leverages epigenetic modifications to read and write biological signals, potentially transforming early disease detection and treatment. With an initial focus on improving the products within the $50B market for blood test developers, Epinoma envisions eventually creating safer, more effective epigenetic medicines.
The company received a Pre Seed Round investment on 21 October 2021 from SeedtoB Capital, signaling investor confidence in their innovative approach and future growth potential. Investors should watch for Epinoma's advancements in protein engineering, given its promising scope and market applicability.
